<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581866</url>
  </required_header>
  <id_info>
    <org_study_id>40349</org_study_id>
    <nct_id>NCT01581866</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of ziprasidone 20&#xD;
      mg capsules versus Geodon 20 mg capsules under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, 2-way crossover, bioequivalence study of Ziprasidone 20 mg capsules and Geodon 20&#xD;
      mg capsules in healthy subjects under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6, 6.50, 7, 8, 9, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ziprasidone HCL Capsules, 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Geodon Capsules, 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geodon Capsules, 20 mg of Pfizer Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone Hydrochloride</intervention_name>
    <description>Ziprasidone HCL Capsules, 20 mg</description>
    <arm_group_label>Geodon Capsules, 20 mg</arm_group_label>
    <arm_group_label>Ziprasidone HCL Capsules, 20 mg</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, smoker or non-smoker, 18 years of age and older.&#xD;
&#xD;
          -  Capable of consent.&#xD;
&#xD;
          -  BMI between 19.0 and 30.0 kg/m2 inclusively.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks prior to the administration of the&#xD;
             study medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 100 or over 140 mmHg, diastolic blood pressure lower than 60 or&#xD;
             over 90 mmHg, or heart rate less than 60 or over 100 bpm) at screening.&#xD;
&#xD;
          -  Qtc &gt; 430 for males and Qtc &gt; 450 for females.&#xD;
&#xD;
          -  History of significant alcohol abuse or drug abuse within one year prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Regular use of alcohol within six months prior to the screening visit ( more than&#xD;
             fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL&#xD;
             of 40% alcohol]).&#xD;
&#xD;
          -  Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or&#xD;
             hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the&#xD;
             screening visit or positive urine drug screen at screening.&#xD;
&#xD;
          -  History of allergic reaction to heparin, ziprasidone, or other related drugs.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;&#xD;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,&#xD;
             imidazole, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms(e.g. diarrhea, vomiting), liver or kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological&#xD;
             endocrinal cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or&#xD;
             metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products (including natural food supplements, vitamins,&#xD;
             garlic as a supplement) within 7 days prior to administration of study medication,&#xD;
             except for topical products without systemic absorption and hormonal contraceptives.&#xD;
&#xD;
          -  Difficulty to swallow study medication.&#xD;
&#xD;
          -  Smoking more than 25 cigarettes per day.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Medical Sub-Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug (other than hormonal contraceptives)&#xD;
             within 3 months prior to administration of study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or&#xD;
             loss of whole blood (excluding the volume of blood that will be drawn during the&#xD;
             screening procedures of this study) prior to administration of the study medication as&#xD;
             follows.&#xD;
&#xD;
               1. 50 mL to 300 mL of whole blood within 30 days,&#xD;
&#xD;
               2. 301 mL to 500 mL of whole blood within 45 days, or&#xD;
&#xD;
               3. more than 500 mL of whole blood within 56 days prior to drug administration.&#xD;
&#xD;
          -  Consumption of food or beverages containing grapefruit (e.g. fresh, canned, or frozen)&#xD;
             within 7 days prior to administration of the study medication.&#xD;
&#xD;
          -  History or known presence of tardive dyskinesia.&#xD;
&#xD;
          -  History of neuroleptic malignant syndrome.&#xD;
&#xD;
          -  History or known presence of clinically significant cardiac diseases (such as heart&#xD;
             failure, QT prolongation, congenital long QT syndrome, myocardial infarction, cardiac&#xD;
             arrhythmias, conduction abnormalities) or other conditions such as electrolyte&#xD;
             disturbance, hypokalemia or hypomagnesemia.&#xD;
&#xD;
          -  Breast-feeding subject.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening.&#xD;
&#xD;
          -  Female subjects of childbearing potential having unprotected sexual intercourse with&#xD;
             any non-steril male partner (i.e male who has not been sterilized by vasectomy for at&#xD;
             least 6 months ) within 14 days prior to study drug administration. Acceptable methods&#xD;
             of contraception.&#xD;
&#xD;
               1. intra-uterine contraceptive device (placed at least 4 weeks prior to study drug&#xD;
                  administration;&#xD;
&#xD;
               2. condom or diaphragm + spermicide;&#xD;
&#xD;
               3. hormonal contraceptives (starting at least 4 weeks prior to study drug&#xD;
                  administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio R. Pizarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Ft. Myers, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Ft. Myers, Inc.</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ziprasidone hydrochloride</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

